AVALO THERAPEUTICS, INC. (AVTX) Debt Components
- 2023-12-31: Notes Payable, CurrentUSD $0.00; Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Notes PayableUSD (m).
- 2023-09-30: Notes Payable, CurrentUSD $0.00; Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Notes PayableUSD (m).
- 2023-06-30: Notes Payable, CurrentUSD $14.12M; Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Notes PayableUSD (m).
- 2023-03-31: Notes Payable, CurrentUSD $9.30M; Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Notes PayableUSD (m).
AVALO THERAPEUTICS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Notes Payable, Current USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Notes Payable USD | Long-term Debt USD | Long-term Debt, Gross USD | Debt, Long-term and Short-term, Combined Amount USD | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $14.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $9.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $5.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $2.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | $33.18M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $32.83M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $32.48M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $17.14M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $1.05M | $14.25M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.05M | $14.28M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $1.05M | $14.30M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $1.05M | $14.33M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $1.05M | $14.35M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $1.05M | $14.38M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $787.50K | $14.59M | (m) | $15.38M | (m) | (m) | $0.00 |
| 2017-12-31 | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | $0.00 |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | $0.00 | (m) |
| 2017-09-30 | (m) | $0.00 | $0.00 | (m) | (m) | $0.00 | (m) | $0.00 |
| 2017-06-30 | (m) | $607.60K | $607.60K | (m) | (m) | $609.57K | (m) | $1.97K |
| 2017-03-31 | (m) | $1.49M | $1.49M | (m) | (m) | $1.50M | (m) | $6.97K |
| 2016-12-31 | (m) | $2.35M | $0.00 | (m) | (m) | $2.37M | $2.35M | $20.36K |
| 2016-09-30 | (m) | $3.19M | (m) | (m) | (m) | $3.23M | $3.19M | $38.97K |
| 2016-06-30 | (m) | $3.39M | $611.10K | (m) | (m) | $4.07M | $4.00M | $63.14K |
| 2016-03-31 | (m) | $3.30M | $1.49M | (m) | (m) | $4.88M | $4.79M | $-92.60K |
| 2015-12-31 | (m) | $3.21M | $2.35M | (m) | (m) | $5.69M | $5.56M | $126.70K |
| 2015-09-30 | (m) | $3.13M | $3.20M | (m) | (m) | $6.48M | $6.32M | $151.95K |
| 2014-12-31 | (m) | $1.91M | $5.31M | (m) | (m) | $7.50M | $7.21M | $285.91K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |